This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Launch/Release Date: October 16, 2025

Activity Expiration Date: September 30, 2026

FACULTY

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics Director

Adult Neurofibromatosis Clinical Program Division of Oncology Sarcoma Section

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Launch Date/Release Date: October 6, 2025

Expiration Date: September 30, 2026

FACULTY

Amy Armstrong, MD

Assistant Professor of Pediatrics

Division of Hematology/Oncology

Neurofibromatosis (NF) Center

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fragmented care, and limited provider awareness of emerging innovations. This podcast, presented by Dr. Robert Terkeltaub, seeks to modernize clinical approaches to gout, accelerate the adoption of new evidence and therapies, and ultimately improve the quality and consistency of care for a patient population long underserved by existing education.

Launch Date/Release Date: September 23, 2025

Expiration Date: August 31, 2026

FACULTY

Robert Terkeltaub, MD

Professor Emeritus of Medicine,

University of California, San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.